Non-peptide

GT20029

Also known as

GT-20029 · GT 20029 · Kintor GT20029 · topical AR PROTAC · androgen receptor degrader topical · Kintor hair PROTAC

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Experimental scalp treatment	GT20029 is designed to remove androgen receptors and is discussed for preserving hair or regrowth, including by people who poorly tolerate finasteride.
Different mechanism	It targets receptors rather than lowering DHT production like finasteride. The discussion concerns topical liquid, not an oral medicine or muscle-building SARM.

Notes

GT20029 is an experimental scalp treatment designed to remove androgen receptors. Hair-loss communities hope it could preserve hair with fewer applications or offer an alternative when finasteride is poorly tolerated. Those hopes currently outweigh verified self-use experience.

A receptor degrader, rather than a DHT-lowering pill. DHT is an androgen involved in pattern hair loss. The community shorthand is to remove the follicle's receivers instead of reducing the hormone itself. PROTAC describes recruiting the cell's protein-disposal machinery. Finasteride lowers DHT production; RU-58841 and pyrilutamide aim to block receptor activity. These are different mechanisms, not interchangeable treatments. EADV Congress 2023: China and US Phase I GT20029 abstracts (Official context · Accessed 2026-09-30)

A topical liquid, not a peptide or muscle-building SARM. The hair discussion concerns scalp solution. Acne gels and homemade products need their own formulation context; a powder bearing the same name does not reproduce the studied liquid. GT20029 Anageninc Market Availability (Community discussion · Accessed 2026-09-30)

Source context — EADV Congress 2023: China and US Phase I GT20029 abstracts: Conference abstracts with Kintor authors; no full clinical datasets or numerical half-life reported. China uses healthy-volunteer back skin and gel/solution, US includes AGA/acne groups; they cannot all be described as scalp-user experiences. Date is congress opening date, not an inferred journal publication date.

Source context — GT20029 Anageninc Market Availability: Commercial availability solicitation in opening is not used as sourcing advice. Patent, synthesis, molecular-weight and safety assertions are unverified. The 'im using it' comment refers to pyrilutamide, not GT20029. Exact publication date not exposed in opened view; relative timestamps not converted.

What people notice

Community expectations	People hope for maintenance and fewer applications; the saved discussions do not establish a typical verified self-use result.
Trial findings	At 12 weeks, two Phase II arms gained about 6.7 and 7.4 hairs/cm² beyond placebo. The 1% twice-weekly arm also improved hair width; 1% daily did not clearly beat placebo.

Notes

Keeping existing hair can be the main goal. The maintenance discussion divides people wanting dramatic regrowth from people who cannot tolerate finasteride or dutasteride and would welcome holding their current hair. That is a useful difference in goals, not evidence GT20029 achieves either for everyone. Isn't GT20029 more exciting from a maintenance and prevention perspective than PP405? (Community discussion · Accessed 2026-09-30)

Fewer scalp applications appeal to people tired of daily liquids. Replies to the Phase II announcement celebrate twice-weekly use. Others temper the excitement because earlier promising Kintor results did not settle their doubts. Convenience remains an attraction; comparison with a tablet or another topical needs actual outcome evidence. GT20029 China Phase II Trial For AGA Reached Primary Endpoint (Community discussion · Accessed 2026-09-30) · When is it time to say goodbye to the research section? (Community opinion · Accessed 2026-09-30)

A short hair-count signal, not a head-to-head victory. The Phase II abstract describes 180 Chinese men treated for 12 weeks. The preserved paper record reports 1 mL per application, seven sprays of its study formulation—not a generic spray conversion or homemade-liquid instruction. Rounded hair-count increases were 16.8 versus 10.1 hairs/cm² for 0.5% daily and 11.9 versus 4.6 for 1% twice weekly. The sponsor's April 2024 report gives differences of 6.69 and 7.36 hairs/cm² beyond placebo, rounding to 6.7 and 7.4; subtracting the rounded group values can change the last decimal. The latter arm also improved hair width; this is not a head-to-head victory over dutasteride. [Sponsor results](https://en.kintor.com.cn/news_details/1803365125008502784.html) Hu et al.: Efficacy and safety of topical GT20029 in male androgenetic alopecia (Official context · Accessed 2026-09-30) · GT20029 Big Phase 2 Update Results! (Community discussion · Accessed 2026-09-30) · Preserved GT20029 Phase II paper/formulation record (Official context · Accessed 2026-09-30)

1% daily did not clearly beat placebo. The update author's irritation and dosing-sweet-spot explanations are speculation. They do not establish a better frequency. GT20029 Big Phase 2 Update Results! (Community discussion · Accessed 2026-09-30)

Source context — Isn't GT20029 more exciting from a maintenance and prevention perspective than PP405?: Expectations and experiences with other drugs, not GT20029 outcome reports. Exact publication date not available in opened view; relative timestamps not converted. KX-826 benefit/no-side-effect claims and PP405 cure predictions excluded.

Source context — GT20029 China Phase II Trial For AGA Reached Primary Endpoint: Sponsor text is promotional trial-origin material, not an independent community effectiveness account. Comments demonstrate attraction and disagreement, not a success rate. Purchase/group-buy replies are excluded.

Source context — When is it time to say goodbye to the research section?: Early expectation, not established frequency or GT20029 self-use. Finasteride symptoms in the opening are not attributed to GT20029. Only page 1 inspected.

Source context — Hu et al.: Efficacy and safety of topical GT20029 in male androgenetic alopecia: Abstract only, not full text. Publisher PDF denied 403 and PubMed opens returned only page furniture. Same Phase II study as numbers circulated in sponsor/community posts; no independent origin or long-term maintenance claim.

Source context — GT20029 Big Phase 2 Update Results!: Trial interpretation, not self-use. Numerical study material shares the GT20029-CN-phase2 origin family; sweet-spot/irritation reasoning is speculation. The Pelage assertion appears to concern a different developer and is not accepted as GT20029 identity evidence.

Source context — Preserved GT20029 Phase II paper/formulation record: Fresh full text returned403. Application volume preserved from previously reviewed formal record; no fresh full-text access claimed. Same origin as PhaseII abstract and circulated results.

Doses people talk about

Trial-based concentrations	0.5% once daily and 1% twice weekly lead the discussion; 0.5% twice weekly and 1% daily were also discussed. These are clinical arms, not measured DIY dose bands.
Volume matters	The preserved study record reports 1 mL per application of its formulation. Percent alone does not give milligrams per application, and generic sprays are not equivalent.

Notes

Scalp solution: 0.5% once daily or 1% twice weekly dominates trial-based talk. These numbers come from clinical arms repeated in forum posts, not measured DIY dose bands. The posts also discuss 0.5% twice weekly and 1% daily. Percent is concentration, not milligrams per application; the amount depends on liquid volume. GT20029 Big Phase 2 Update Results! (Community discussion · Accessed 2026-09-30) · GT20029 China Phase II Trial For AGA Reached Primary Endpoint (Community discussion · Accessed 2026-09-30)

Half-life, onset & duration

Visible onset	Week 6 and week 12 are trial checks, not a verified typical onset for self-users.
Effect duration	Single-application coverage and lasting gains after stopping are not established. Receptor-return expectations are discussion, not measured maintenance data.
Half-life	No usable numerical human half-life is supplied. Often very low blood concentrations and a twice-weekly schedule cannot establish it.

Notes

Week 6 and week 12 are trial checks, not typical user onset. The results post supplies no verified self-use timeline for first visible regrowth. The original discussion cautions against expecting new hairs within one month. GT20029 Big Phase 2 Update Results! (Community discussion · Accessed 2026-09-30)

Neither single-application coverage nor lasting gains after stopping are established. A permanence thread asks whether a few applications could end pattern hair loss. Replies expect receptors to return and repeated treatment to remain necessary, while admitting the frequency is unknown. These are mechanism-based expectations, not a measured washout or maintenance diary. Will GT20029 results be permanent? (Community discussion · Accessed 2026-09-30)

No measured human half-life emerges from these discussions. Early posts floated once-weekly or even fortnightly application. Those are schedule guesses, not blood-clearance measurements. A drug leaving the blood, a receptor being replaced and a hair benefit fading are three different clocks; twice-weekly trial use does not make them equivalent. When is it time to say goodbye to the research section? (Community opinion · Accessed 2026-09-30) · GT20029 Anageninc Market Availability (Community discussion · Accessed 2026-09-30) · Will GT20029 results be permanent? (Community discussion · Accessed 2026-09-30)

Low blood concentrations do not provide a numerical half-life. Phase I abstracts assessed half-life but reported no usable value. Measurements were often near or below the 1 pg/mL quantification limit. EADV Congress 2023: China and US Phase I GT20029 abstracts (Official context · Accessed 2026-09-30)

Source context — Will GT20029 results be permanent?: Mechanism-based expectations without measured receptor-regeneration, half-life or post-withdrawal outcome data. No inferred publication date; release-date guesses omitted.

Cycles people discuss

Maintenance discussion	People discuss continuing use, sometimes added to a minoxidil/finasteride base. A 12-week study does not establish an on/off cycle or a reason to stop that base.

Notes

Ongoing maintenance is the discussion model; no established on/off cycle. Commenters compare continued scalp use with taking a daily finasteride tablet. A 12-week experiment is not an eight-week blast or evidence for scheduled breaks. Existing stack discussions describe an addition to a minoxidil or finasteride base, rather than a proven reason to stop that base. Will GT20029 results be permanent? (Community discussion · Accessed 2026-09-30) · GT20029 (Hair boosting) discussion (Community opinion · Accessed 2026-09-30)

Source context — GT20029 (Hair boosting) discussion: Speculative bro-science, not a measured duration or self-use report. Original opening contains unsupported mechanism and safety claims; none accepted. Derived public article text limited to the continuing-use comparison.

Stacks

Proposed combinations	Minoxidil, finasteride/dutasteride, pyrilutamide, RU-58841, clascoterone and PP405 appear in stack talk. These are proposed combinations, not proven combined outcomes.

Notes

Replacement and add-on are competing hopes. Some maintenance-thread commenters want an escape from finasteride side effects; another imagines using GT20029 alongside it. The wider stack talk includes minoxidil, finasteride, dutasteride, pyrilutamide, RU-58841, clascoterone and PP405. Different mechanisms support a hypothesis, not proven combination results. Isn't GT20029 more exciting from a maintenance and prevention perspective than PP405? (Community discussion · Accessed 2026-09-30) · GT20029 Big Phase 2 Update Results! (Community discussion · Accessed 2026-09-30)

Watch for

Application-site effects	Trials reported dryness, itching, rash, peeling and local pain. Formulation matters; these are trial findings rather than typical DIY reports.
Systemic and pregnancy uncertainty	Scalp application does not guarantee zero whole-body effects. Pregnancy safety, women's experience and combinations remain uncertain.
Product and report mix-ups	Homemade liquid is not the study formulation. Some apparent user results and headache reports actually concern other hair compounds.

Notes

Dryness, itching, rash, peeling and local pain occurred in trials. These are Phase I application-site findings, not a typical DIY user's feeling. The vehicle and formulation also matter. EADV Congress 2023: China and US Phase I GT20029 abstracts (Official context · Accessed 2026-09-30)

Local treatment does not guarantee zero whole-body effects. Community arguments about molecule size and skin penetration pull in opposite directions. Neither settles systemic safety for an unknown formulation. Reports of problems on other anti-androgens explain concern but cannot establish GT20029's effects. GT20029 Anageninc Market Availability (Community discussion · Accessed 2026-09-30) · A concern regarding the upcoming androgen degrader drug GT20029 (Community discussion · Accessed 2026-09-30)

Pregnancy, women's use and combinations remain uncertain. The original record flags thin female-pattern experience and pregnancy concerns around androgen-targeting treatment. It supplies no pregnancy safety evidence or established interaction map. Adding another receptor-targeting topical is not shown safe simply because the mechanisms sound compatible. A concern regarding the upcoming androgen degrader drug GT20029 (Community discussion · Accessed 2026-09-30)

Apparent user results can belong to a different compound. In the market thread, a reply saying the writer was using it refers to pyrilutamide in the preceding exchange. Likewise, headache reports in the concern thread name RU, pyrilutamide and topilutamide; GT20029 adverse reports are secondhand and questioned by another commenter. They cannot become confirmed GT20029 diaries. GT20029 Anageninc Market Availability (Community discussion · Accessed 2026-09-30) · A concern regarding the upcoming androgen degrader drug GT20029 (Community discussion · Accessed 2026-09-30)

Practical topical habits are preferences, not tested instructions. Community routines favor evening use apart from morning minoxidil, drying before layering and keeping bottles cool, dark and capped. They establish neither a preferred application hour nor GT20029-specific stability. Homemade alcohol/propylene-glycol liquid and the trial formulation cannot be assumed equivalent.

Source context — A concern regarding the upcoming androgen degrader drug GT20029: No firsthand GT20029 adverse account. Other-drug headaches and GT hearsay stay distinct. Deleted replies and more-replies branches were unavailable. Hair-texture and automated fact-check bot assertions are not accepted.

Full notes

What GT20029 does differently

A receptor degrader, rather than a DHT-lowering pill. DHT is an androgen involved in pattern hair loss. The community shorthand is to remove the follicle's receivers instead of reducing the hormone itself. PROTAC describes recruiting the cell's protein-disposal machinery. Finasteride lowers DHT production; RU-58841 and pyrilutamide aim to block receptor activity. These are different mechanisms, not interchangeable treatments. Official context Community
A topical liquid, not a peptide or muscle-building SARM. The hair discussion concerns scalp solution. Acne gels and homemade products need their own formulation context; a powder bearing the same name does not reproduce the studied liquid. Reddit r/tressless Community

What people hope to gain

Keeping existing hair can be the main goal. The maintenance discussion divides people wanting dramatic regrowth from people who cannot tolerate finasteride or dutasteride and would welcome holding their current hair. That is a useful difference in goals, not evidence GT20029 achieves either for everyone. Reddit r/tressless
Fewer scalp applications appeal to people tired of daily liquids. Replies to the Phase II announcement celebrate twice-weekly use. Others temper the excitement because earlier promising Kintor results did not settle their doubts. Convenience remains an attraction; comparison with a tablet or another topical needs actual outcome evidence. Reddit r/tressless HairLossTalk

Doses people discuss

Scalp solution: 0.5% once daily or 1% twice weekly dominates trial-based talk. These numbers come from clinical arms repeated in forum posts, not measured DIY dose bands. The posts also discuss 0.5% twice weekly and 1% daily. Percent is concentration, not milligrams per application; the amount depends on liquid volume. Reddit r/tressless Reddit r/tressless
1% daily did not clearly beat placebo. The update author's irritation and dosing-sweet-spot explanations are speculation. They do not establish a better frequency. Reddit r/tressless

Half-life

No measured human half-life emerges from these discussions. Early posts floated once-weekly or even fortnightly application. Those are schedule guesses, not blood-clearance measurements. A drug leaving the blood, a receptor being replaced and a hair benefit fading are three different clocks; twice-weekly trial use does not make them equivalent. HairLossTalk Reddit r/tressless Reddit r/tressless

Onset: when change might appear

Week 6 and week 12 are trial checks, not typical user onset. The results post supplies no verified self-use timeline for first visible regrowth. The original discussion cautions against expecting new hairs within one month. Reddit r/tressless Community

Duration: how long an effect lasts

Neither single-application coverage nor lasting gains after stopping are established. A permanence thread asks whether a few applications could end pattern hair loss. Replies expect receptors to return and repeated treatment to remain necessary, while admitting the frequency is unknown. These are mechanism-based expectations, not a measured washout or maintenance diary. Reddit r/tressless

Cycles and ongoing use

Ongoing maintenance is the discussion model; no established on/off cycle. Commenters compare continued scalp use with taking a daily finasteride tablet. A 12-week experiment is not an eight-week blast or evidence for scheduled breaks. Existing stack discussions describe an addition to a minoxidil or finasteride base, rather than a proven reason to stop that base. Reddit r/tressless Looksmax.org Community

What deserves attention

Local treatment does not guarantee zero whole-body effects. Community arguments about molecule size and skin penetration pull in opposite directions. Neither settles systemic safety for an unknown formulation. Reports of problems on other anti-androgens explain concern but cannot establish GT20029's effects. Reddit r/tressless Reddit r/tressless
Dryness, itching, rash, peeling and local pain occurred in trials. These are Phase I application-site findings, not a typical DIY user's feeling. The vehicle and formulation also matter. Official context
Pregnancy, women's use and combinations remain uncertain. The original record flags thin female-pattern experience and pregnancy concerns around androgen-targeting treatment. It supplies no pregnancy safety evidence or established interaction map. Adding another receptor-targeting topical is not shown safe simply because the mechanisms sound compatible. Community Reddit r/tressless

What the community discussions add

Replacement and add-on are competing hopes. Some maintenance-thread commenters want an escape from finasteride side effects; another imagines using GT20029 alongside it. The wider stack talk includes minoxidil, finasteride, dutasteride, pyrilutamide, RU-58841, clascoterone and PP405. Different mechanisms support a hypothesis, not proven combination results. Reddit r/tressless Reddit r/tressless Community
People with prior bad experiences may still want to preserve hair. On Propeciahelp, ithought hoped GT20029 might support hair preservation after stopping finasteride. Sugarhouse worried that directly targeting receptors could create similar problems. Neither had tried GT20029; their exchange shows why an alternative can be attractive and worrying at the same time. Propeciahelp
Apparent user results can belong to a different compound. In the market thread, a reply saying the writer was using it refers to pyrilutamide in the preceding exchange. Likewise, headache reports in the concern thread name RU, pyrilutamide and topilutamide; GT20029 adverse reports are secondhand and questioned by another commenter. They cannot become confirmed GT20029 diaries. Reddit r/tressless Reddit r/tressless
Practical topical habits are preferences, not tested instructions. Community routines favor evening use apart from morning minoxidil, drying before layering and keeping bottles cool, dark and capped. They establish neither a preferred application hour nor GT20029-specific stability. Homemade alcohol/propylene-glycol liquid and the trial formulation cannot be assumed equivalent. Community
No-change explanations can become excuses. The original discussion blames disappointing results on identity, concentration or impatience. Those possibilities do not prove why nothing changed. An August 2026 update thread still contains both confidence and distrust; its claims of guaranteed effectiveness and release dates exceed the evidence. Community Reddit r/tressless

What the human studies actually add

A short hair-count signal, not a head-to-head victory. The Phase II abstract describes 180 Chinese men treated for 12 weeks. The preserved paper record reports 1 mL per application, seven sprays of its study formulation—not a generic spray conversion or homemade-liquid instruction. Rounded hair-count increases were 16.8 versus 10.1 hairs/cm² for 0.5% daily and 11.9 versus 4.6 for 1% twice weekly. The sponsor's April 2024 report gives differences of 6.69 and 7.36 hairs/cm² beyond placebo, rounding to 6.7 and 7.4; subtracting the rounded group values can change the last decimal. The latter arm also improved hair width; this is not a head-to-head victory over dutasteride. [Sponsor results](https://en.kintor.com.cn/news_details/1803365125008502784.html) Official context Reddit r/tressless Official context
Low blood concentrations do not provide a numerical half-life. Phase I abstracts assessed half-life but reported no usable value. Measurements were often near or below the 1 pg/mL quantification limit. Official context